[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatectomy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,48,79,99,128,151,175,201,224,251,282,317,347,372,397],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100626027","hybrid-closed-loop-insulin-delivery-after-pancreatectomy-100626027",false,"NCT07430293","Hybrid Closed-Loop Insulin Delivery After Pancreatectomy","Metabolic Effects of Hybrid Closed-loop Insulin Delivery in People With Diabetes After Pancreatectomy: a Randomized Cross-over Controlled Trial","HCL PP","Inclusion Criteria:\n\n1. Age from 18 years\n2. History of total or partial pancreatectomy with random C-peptide \\\u003C 0.3 ng\u002FmL and concomitant blood glucose between 120 and 225 mg\u002FdL (no minimum delay required since surgery)\n3. Total daily insulin dose between 6 units and 250 units\n4. Be affiliated to a French social security scheme\n5. Individual able and willing to provide written informed consent\n\nExclusion Criteria:\n\n1. Presence of diabetic retinopathy at or beyond severe non-proliferative diabetic retinopathy, not stabilized by ophthalmologic treatment\n2. Usual diabetes treatment with an insulin pump coupled with continuous glucose monitoring with a \"suspend before hypoglycemia\" system\n3. Pregnant woman or planned pregnancy within the next 6 months\n4. Planned chemotherapy within the next 6 months\n5. Enteral or parenteral nutrition\n6. Estimated life expectancy less than 12 months\n7. Cognitive or psychiatric disorders compromising the individual's autonomy to manage automated insulin delivery\n8. Person taking part in another research study or with an exclusion period still in progress\n9. Individual under legal guardianship or curatorship\n10. Any contraindication mentioned in the instructions for use of the MiniMed 780 - Simplera\n11. Imprisoned or otherwise deprived of liberty","ALL","18 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"NA","Individuals with diabetes secondary to pancreatectomy experience impaired quality of life, partly due to the challenges of managing highly variable blood glucose levels. Hybrid closed-loop (HCL) automated insulin delivery (AID) systems, widely evaluated in type 1 diabetes, may improve both metabolic outcomes and quality of life in this population.\n\nA review of the literature identified a few observational studies reporting promising results with HCL systems in the context of post-pancreatectomy diabetes. Only one randomized trial has evaluated AID in this population, showing excellent outcomes, but using a complex bihormonal system that is not yet commercially available worldwide. Consequently, there remains a lack of confirmatory evidence regarding the efficacy of commercially available monohormonal HCL systems in individuals with diabetes secondary to pancreatectomy, evidence that is crucial to support broader access to this technology.\n\nThe intervention will consist in a 3-month AID treatment combining MiniMed 780 and Simplera.\n\nThe control period will consist in 3 months using the Simplera for continuous glucose monitoring, alongside participant usual diabetes treatment.\n\nThe primary outcome is the percentage of time that interstitial glucose levels remain within the target range (70-180 mg\u002FdL), as measured by continuous glucose monitoring (CGM, Simplera), over a 3-month period using the MiniMed 780 hybrid closed-loop system, compared to a 3-month period under the participant's usual diabetes treatment.",[27,28,29],"Pancreatectomy","Total Pancreatectomy","Partial Pancreatectomy",[31,32,33,34],"diabetes","pancreatectomy","hybrid cloosed-loop","automatised insulin delivery","RECRUITING","2026-05-26",{"date":38,"type":39},"2026-05-28","ACTUAL",{"date":41,"type":39},"2026-05-19",{"date":43,"type":21},"2027-11-19",{"name":45,"class":46},"Centre Hospitalier Sud Francilien","OTHER",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100639244","clinical-oncologic-and-metabolic-effects-of-pancreatic-mass-loss-after-pancreatectomy-in-non-diabetic-patients-100639244","NCT07608055","Clinical, Oncologic, and Metabolic Effects of Pancreatic Mass Loss After Pancreatectomy in Non-Diabetic Patients","Clinical, Oncologic, and Metabolic Effects of Pancreatic Mass Loss Following Partial, Near-Total, and Total Pancreatectomy in Patients Without Diabetes at Baseline: A Monocentric Ambispective Observational Study","DCP-NDM","Inclusion Criteria:\n\n* Adult patients (≥18 years)\n* No diabetes mellitus at baseline\n* Undergoing partial, near-total, or total pancreatectomy at the study center\n* Availability of clinical and metabolic data according to study component\n* Written informed consent for the prospective component\n\nExclusion Criteria:\n\n* Diabetes mellitus at baseline\n* Age \\\u003C18 years\n* Missing key clinical data precluding eligibility assessment or primary outcome evaluation\n* Refusal or inability to provide informed consent for the prospective component, where applicable",{"count":57,"type":21},579,"OBSERVATIONAL","This study will examine how removal of part or all of the pancreas affects blood sugar control, metabolism, and clinical outcomes over time.\n\nThe study will include adults without diabetes before surgery who undergo pancreatic surgery as part of routine clinical care at Fondazione Policlinico Universitario A. Gemelli IRCCS.\n\nResearchers will study whether participants develop diabetes after surgery and whether this risk changes according to the type of pancreatic resection.\n\nInformation from routine clinical care, metabolic tests, imaging, and pancreatic tissue samples collected during surgery may be used for research analyses.",[27,61,62],"Diabetes Mellitus Type 2","Pancreatic Neoplasms",[27,64,65,66,67],"New-Onset Diabetes","Pancreatic Surgery","Beta-Cell Function","type 2 diabetes","NOT_YET_RECRUITING","2026-05-21",{"date":71,"type":39},"2026-05-27",{"date":73,"type":21},"2026-05",{"date":75,"type":21},"2041-05",{"name":77,"class":46},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":98,"locationsCount":4},"100637884","clinical-oncological-and-metabolic-effects-of-pancreatic-mass-loss-after-partial-near-total-and-total-pancreatectomy-in-patients-with-preoperative-diabetes-mellitus-100637884","NCT07607912","Clinical, Oncological and Metabolic Effects of Pancreatic Mass Loss After Partial, Near-total and Total Pancreatectomy in Patients With Preoperative Diabetes Mellitus","Clinical, Oncological and Metabolic Effects of Pancreatic Mass Loss After Partial, Near-total and Total Pancreatectomy in Patients With Preoperative Diabetes Mellitus: A Monocentric Ambispective Observational Study","DCP-DM","Inclusion Criteria:\n\n* Adult patients (≥18 years)\n* Diabetes mellitus at baseline\n* Undergoing partial, near-total, or total pancreatectomy at the study center for benign or malignant pancreatic disease\n* Availability of clinical and metabolic follow-up data according to study component\n* Written informed consent for the ambispective and prospective components, where applicable\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Absence of diabetes mellitus at baseline\n* Missing essential clinical data or incomplete follow-up precluding evaluation of study outcomes\n* Severe pre-existing non-oncologic clinical conditions with life expectancy \\\u003C6 months\n* Refusal, withdrawal, or inability to provide informed consent for the ambispective and prospective components, where applicable",{"count":88,"type":21},408,"This study will examine how removal of part or all of the pancreas affects blood sugar control, metabolism, and clinical outcomes over time.\n\nThe study will include adults with diabetes before surgery who undergo pancreatic surgery as part of routine clinical care at Fondazione Policlinico Universitario A. Gemelli IRCCS.\n\nResearchers will study whether glycemic control worsens after surgery and whether this risk changes according to the type of pancreatic resection. The study will also examine changes in glucose metabolism, and cancer-related outcomes.\n\nInformation from routine clinical care, metabolic tests, imaging, and pancreatic tissue samples collected during surgery may be used for research analyses.",[61,27,62],[61,92,93,94,27],"Metabolism","Beta Cells Function","Glycemic Control",{"date":36,"type":39},{"date":73,"type":21},{"date":75,"type":21},{"name":77,"class":46},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":116,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":47},"100633892","patients-with-pancreatic-tumor-use-of-an-app-to-monitor-progress-in-a-simple-and-intuitive-way-by-periodically-completing-targeted-questionnaires-and-providing-educational-and-informational-content-pancreasplus-100633892","NCT07532590","Patients With Pancreatic Tumor: Use of an App to Monitor Progress in a Simple and Intuitive Way by Periodically Completing Targeted Questionnaires and Providing Educational and Informational Content (PancreasPlus).","A Prospective Study on the Use of an App (PancreasPlus) for Home Monitoring and Proactive Management of Patients With Pancreatic Cancer.","Inclusion Criteria:\n\n* Age ≥18; diagnosis of pancreatic cancer (histological\u002Fcytological)\n* Access to a smartphone or tablet and a data connection; basic digital literacy or a caregiver available,\n* Ability to understand and provide informed consent; understanding of the Italian language.\n\nExclusion Criteria:\n\n* Severe uncompensated cognitive impairment,\n* Social or logistical circumstances that prevent follow-up or access to\u002Fuse of the app,\n* Refusal or withdrawal of consent.",{"count":107,"type":21},185,[24],"Caring for people with pancreatic cancer requires good coordination between hospital care and care at home, with different healthcare professionals working closely together. Patients are also becoming more involved in managing their own care on a daily basis. However, this active involvement can be difficult if there is poor communication with healthcare teams, differences in skills or familiarity with digital tools, or systems that do not support patient participation.\n\nThe PancreasPlus app was developed to support patients and caregivers by providing reliable information, self-monitoring tools, and a communication channel with healthcare professionals. The study aims to assess the feasibility, patient engagement, and perceived quality of routine use of the app. It is hypothesized that its use will improve engagement, perceived quality, reduce anxiety and unplanned hospital visits, without introducing technological or privacy risks. The app supports information and data collection but does not replace clinical decision-making.\n\nObjectives\n\nPrimary objectives:\n\nAssess feasibility and patient engagement through questionnaire completion. Evaluate perceived service quality using the Client Satisfaction Questionnaire (CSQ-8).\n\nSecondary objectives:\n\nMonitor unplanned hospital visits and adherence to chemotherapy. Assess anxiety (HADS-A), nutritional status, and global quality of life (PROMIS Global).\n\nEvaluate usability and acceptability of the app (SUS, UTAUT2 short version).\n\nEndpoints Primary endpoints include questionnaire completion rates and perceived quality (CSQ-8 score). Secondary endpoints include unplanned hospital access, chemotherapy adherence, anxiety levels, nutritional status, quality of life, and app usability\u002Facceptability.\n\nMethods This is a prospective, interventional, multicenter study with consecutive enrollment of eligible patients. Each participant will be followed for 3 months, with most activities conducted remotely via the app.\n\nAt baseline (T0), patients receive study information, provide consent, undergo training, register in the app, and complete initial assessments (clinical, socio-demographic, PROMIS Global, HADS-A). At 12 weeks (W12), follow-up includes all outcome questionnaires and data on unplanned hospital visits.\n\nThe app includes features such as a personal diary (symptoms, weight, BMI, appointments), interactive questionnaires with tailored feedback, and educational content on nutrition, prevention, emotional support, and patient rights.\n\nPopulation Inclusion criteria: adults (≥18 years) with pancreatic cancer, access to a smartphone\u002Ftablet (or caregiver support), ability to consent, and understanding of Italian. Exclusion criteria include severe cognitive impairment, inability to use the app or complete follow-up, or withdrawal of consent.\n\nSample Size and Analysis A total of 185 patients will be enrolled (accounting for 10% dropout), based on an expected 70% engagement rate. Analyses will be conducted on both intention-to-observe and per-protocol populations. Engagement will be analyzed as questionnaire completion rates, while other outcomes will be analyzed using appropriate statistical models (e.g., logistic regression, ANCOVA, descriptive statistics). An interim analysis at 50% enrollment is planned to address potential low engagement.",[111,27,112,113,114,115],"Ductal Adenocarcinoma of Pancreas","Caregiver","Nutritional Evaluation","Post Surgery Patients","Pain Management",[117,118],"App","Quality of life","2026-05-06",{"date":121,"type":39},"2026-05-11",{"date":123,"type":39},"2026-02-26",{"date":125,"type":21},"2027-04",{"name":127,"class":46},"Casa di Cura Dott. Pederzoli",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":78},"100634537","postoperative-insulin-intervention-after-pancreatectomy-in-ndm-patients-100634537","NCT07540975","Postoperative Insulin Intervention After Pancreatectomy in nDM Patients","Effects of Insulin Intervention After Pancreatectomy in Preoperative Non-diabetic Patients : Randomized Non-inferiority Clinical Trial","Inclusion Criteria:\n\n* Adults aged 18 to 80 years\n* Patients without a prior diagnosis of diabetes mellitus\n* Patients scheduled to undergo pancreatectomy for periampullary tumors or pancreatic tumors\n* Ability to understand the study and provide written informed consent\n\nExclusion Criteria:\n\n* Patients diagnosed with pancreatic adenocarcinoma\n* Patients undergoing total pancreatectomy\n* Patients undergoing hepatopancreatoduodenectomy (HPD) or with a history of prior hepatectomy\n* Patients with severe comorbidities (e.g., liver cirrhosis, chronic kidney disease, or heart failure)\n* Patients currently enrolled in another clinical trial that may interfere with this study","80 Years",{"count":137,"type":21},290,[24],"The goal of this randomized non-inferiority clinical trial is to evaluate whether routine postoperative insulin infusion can be safely omitted in preoperative non-diabetic adult patients undergoing pancreatectomy for periampullary or pancreatic tumors. The primary purpose is to determine whether withholding insulin infusion provides comparable glycemic control while reducing treatment-related burden and adverse events.\n\nThe main questions it aims to answer are:\n\n* Does omission of postoperative insulin infusion result in non-inferior mean blood glucose levels through postoperative day (POD) 3 compared to standard insulin infusion?\n* Does omission of insulin infusion reduce the incidence of hypoglycemia without increasing postoperative complications, including surgical site infection within 3 months?\n\nResearchers will compare a no-insulin infusion group (intervention arm) with a standard insulin infusion group (control arm) to determine whether avoiding routine insulin infusion maintains comparable glycemic control while improving safety and patient comfort.\n\nParticipants will:\n\n* Undergo pancreatectomy and be randomly assigned (1:1) to either receive standard insulin infusion or no routine insulin infusion postoperatively\n* Have blood glucose monitored using intermittent testing and continuous glucose monitoring (flash glucose monitoring system)\n* Receive protocol-based glycemic management, including rescue insulin if hyperglycemia occurs or discontinuation if hypoglycemia develops\n* Be followed for up to 3 months postoperatively to assess glycemic outcomes, hypoglycemic events, surgical site infection, and other postoperative complications\n* Complete a questionnaire assessing discomfort related to glucose monitoring and insulin administration\n\nThis study aims to establish evidence-based postoperative glucose management strategies for non-diabetic patients undergoing pancreatectomy.",[141,27],"Postoperative Hyperglycemia","2026-04-15",{"date":144,"type":39},"2026-04-21",{"date":146,"type":21},"2026-05-18",{"date":148,"type":21},"2030-03-31",{"name":150,"class":46},"Dae Wook Hwang",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":78},"100585539","utility-of-trypsinogen--2-in-early-detection-and-follow-up-of-post-pancreatectomy-acute-pancreatitis-ppap-100585539","NCT06903676","Utility of Trypsinogen -2 in Early Detection and Follow Up of Post-pancreatectomy Acute Pancreatitis (PPAP)","Inclusion Criteria:\n\n* Older than 18 years of age\n* Undergoing elective pancreatectomy for any indication\n\nExclusion Criteria:\n\n* Younger than 18 years of age\n* Pregnant women\n* Prisoner",{"count":158,"type":21},50,[24],"The goal of this study is to learn if urine trypsinogen can be used to diagnose post-pancreatectomy acute pancreatitis in patients undergoing pancreatectomy.\n\nParticipants will have their urine measured by dipsticks during and after their surgery.",[162,27],"Pancreatitis",[27,164,165],"Post-pancreatectomy acute pancreatitis","PPAP","2026-03-10",{"date":168,"type":39},"2026-03-12",{"date":170,"type":39},"2025-08-05",{"date":172,"type":21},"2026-04",{"name":174,"class":46},"Indiana University",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":186,"conditions":187,"keywords":190,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":78},"100494604","phase-3-is-intraperitoneal-drainage-necessary-following-distal-pancreatectomy-100494604","NCT05720338","Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?","Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy: A Randomized Control Trial","Inclusion Criteria:\n\n* Subjects must be undergoing a scheduled distal pancreatectomy (with or without concurrent splenectomy)\n* Age ≥18 years\n* Subjects must have the ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years old\n* Patients who are pregnant\n* Patients with a history of previous pancreatic surgery\n* Patients with a history of prior gastric resection, gastric bypass or sleeve gastrectomy\n* Patients with prior cystogastrostomy procedure\n* Patients who have failed prior endoscopic intervention or ultrasound due to esophageal or other gastrointestinal stricture\n* Patients with Type 3 or Type 4 Paraesophageal Hernia noted either on pre-operative imaging or intra-operatively\n* Patients undergoing concurrent resection of organs other than the pancreas or spleen or gallbladder\n* Patients who undergo oversewing of the pancreatic transection margin\n* Patients with unexpected intraoperative bleeding or adhesive disease which deem it unsafe to proceed without an intraabdominal drain\n* Patients who are unable to provide informed consent",{"count":183,"type":21},234,[185],"PHASE3","The goal of this clinical trial is to analyze if intraperitoneal drainage is necessary following distal pancreatectomy. This study aims to determine whether the omission of routine intraperitoneal drainage in the setting of reinforced staple technology is non-inferior to routine intraperitoneal drainage with respect to a composite post-operative complications of Grade B or C Postoperative pancreatic fistula (POPF), readmission, or organ space surgical site infection following a distal pancreatectomy.",[188,27,189],"Cyst of Pancreas","Pancreas Neoplasm",[191],"Pancreatic neoplasm","2026-02-17",{"date":194,"type":39},"2026-02-19",{"date":196,"type":39},"2023-04-13",{"date":198,"type":21},"2027-07-31",{"name":200,"class":46},"Case Comprehensive Cancer Center",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":78},"100525812","incidence-and-clinical-impact-of-serum-hyperamylasemia-poh-after-pancreatectomy-on-postoperative-outcome-and-patient-safety-100525812","NCT06126601","Incidence and Clinical Impact of Serum Hyperamylasemia (POH) After Pancreatectomy on Postoperative Outcome and Patient Safety","HYPPO","Inclusion Criteria:\n\n* All patients undergoing pancreatic resection for malignant and benign disease with or without pancreatic anastomosis\n* Patients aged 18-85 years\n* Willingness to participate as demonstrated by giving a written informed consent.\n\nExclusion Criteria:\n\n* Necrosectomy (endoscopic or open) for primary acute pancreatitis or within laparotomy\n* Age less than 18 years\n* Surgical drainage procedures without pancreatic resection (cystojejunostomy for pancreatic pseudocysts)\n* One-stage total pancreatectomy\n* Missing written consent","85 Years",{"count":210,"type":21},150,"Recent evidence suggests that postoperative hyperamylasemia (POH) is a predictor of morbidity after pancreatectomy. This is based on the assumption that pancreatitis after pancreatectomy (PPAP) is a major trigger for the development of complications and is indicated by hyperamylasemia. Standardized prospective analysis and correlation with other laboratory parameters, hasn't been performed to date.\n\nTherefore the overall study aims are:\n\n* To prospectively evaluate the incidence and assess the clinical value of biochemical changes for the postoperative course.\n* To confirm and improve the definition and classification of postpancreatectomy acute pancreatitis (PPAP) of the International Study Group of Pancreatic Surgery (ISGPS) and to provide knowledge for effective early management of complications.",[27,213,214],"Hyperamylasemia","Pancreatitis, Acute","2026-02-02",{"date":217,"type":39},"2026-02-03",{"date":219,"type":39},"2023-07-18",{"date":221,"type":21},"2026-07",{"name":223,"class":46},"Technische Universität Dresden",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":233,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":78},"100515542","pancreaticoduodenectomies-with-complete-arterial-coverage-by-retromesenteric-omentoplasty-100515542","NCT05992857","Pancreaticoduodenectomies With Complete Arterial Coverage by Retromesenteric Omentoplasty","Randomized Controlled Trial Comparing Pancreaticoduodenectomies With or Without Complete Arterial Coverage by Omentoplasty in Patients With High Risk of Postoperative Pancreatic Fistula.","PACOMARCO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients requiring a pancreaticoduodenectomy (PD) for any indication\n* Open approach\n* Affiliation to the French public healthcare insurance\n* Fistula risk score (FRS) ≥ 7 confirmed intraoperatively\n* Ability to understand and to comply with the study protocol\n* Reconstruction with PJ and external pancreatic stent\n* Signed written informed consent\n* Inclusion is allowed for patients:\n\n  * On curative or long-term anticoagulation or aspirin (indicated for previous thromboembolic complications, heart disease, previous history of stroke)\n  * Undergoing PD with venous resection\n\nExclusion Criteria:\n\n* Presence of distant tumor deposits (liver and peritoneal metastases, and\u002For para-aortic lymph nodes metastases) reveals during intraoperative exploration for patient with malignant pancreatic or periampullary tumor.\n* Patients with previous abdominal surgery compromising completion of retromesenteric omentoplasty\n* PD with arterial resection (i.e. resection of hepatic artery, splenic artery, superior mesenteric artery, or celiac axis)\n* Laparoscopic or robotic PD\n* Reconstruction wih pancreatico-gastrostomy\n* Total pancreatectomy\n* Emergency procedure\n* Pregnant women\n* Patient under guardianship and curatorship\n* Participation in another interventional study evaluating complication after pancreaticoduodenectomy or patient still being in the exclusion period at the end of a previous study evaluating drugs.",{"count":210,"type":21},[24],"To assess the efficacy of complete covering using retromesenteric omentoplasty vs. partial covering or no covering of peripancreatic arteries in decreasing incidence of grade B+C post-pancreatectomy hemorrhage (PPH), i.e. treated by transfusion and \u002F or radiological or surgical hemostasis after PD in patients with high risk of POPF.",[27,236],"Complication of Surgical Procedure",[238,239,240,241],"Pancreaticoduodenectomy","Post-pancreatectomy haemorrhage","Omentoplasty","Post-operative pancreatic fistula","2025-11-17",{"date":244,"type":39},"2025-11-18",{"date":246,"type":39},"2024-10-22",{"date":248,"type":21},"2027-01",{"name":250,"class":46},"Assistance Publique - Hôpitaux de Paris",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":259,"targetDuration":261,"studyType":58,"phases":4,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":281},"100605060","oncological-safety-of-spleen-preservation-in-left-pancreatectomy-for-pancreatic-ductal-adenocarcinoma-splendid-100605060","NCT07157605","Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)","Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID): Study Protocol for a Prospective Observational International Multicenter Study","SPLENDID","Inclusion Criteria:\n\n* All consecutive adult patients (≥ 18 years) who undergo an open or minimally invasive (i.e., robot-assisted or laparoscopic) left-sided pancreatectomy with concomitant splenectomy for primary resectable, borderline resectable, and locally advanced left-sided PDAC\n\nExclusion Criteria:\n\n* Tumor involvement or abutment of the spleen",{"count":260,"type":21},94,"5 Years","The goal of this observational study is to determine how often lymph node metastases occur in the splenic hilum and surrounding fat in patients with left-sided pancreatic cancer.\n\nThe main question the study aims to answer is:\n\nIs spleen removal necessary in all cases, or is the risk of lymph node metastases in the fat around the spleen low enough to reconsider this standard practice?\n\nCurrently, spleen removal is part of the standard treatment for patients with left-sided pancreatic cancer to ensure that any potential lymph node metastases in the surrounding fat are also removed. However, the likelihood of metastases in this area is low, and spleen removal carries risks.\n\nThis study is a first step toward changing the treatment approach. If the findings show that metastases in the fat around the spleen are rare, the next step will be a randomized trial to further investigate whether spleen removal is necessary.",[264,27],"Pancreatic Cancer Resectable",[266,267,268,269,270,271],"pancreatic adenocarcinoma","PDAC","left pancreatectomy","distal pancreatectomy","splenectomy","splenic hilum","2025-08-28",{"date":274,"type":39},"2025-09-05",{"date":276,"type":39},"2024-11-28",{"date":278,"type":21},"2031-01-01",{"name":280,"class":46},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",10,{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":293,"conditions":294,"keywords":303,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":78},"100588255","laparoscopic-versus-robot-assisted-left-sided-pancreatectomy-for-benign-and-pre-malignant-lesions-diploma-3-100588255","NCT06939023","Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3)","Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3): an International Multicenter Patient-blinded Randomized Controlled Trial","DIPLOMA-3","Inclusion Criteria:\n\n* Age at least 18 years;\n* Indication for elective left-sided pancreatectomy, either spleen-preserving or non-preserving (because of proven or suspected left-sided benign or premalignant disease);\n* Both robot-assisted and laparoscopic left-sided pancreatectomy are technically feasible for resection, according to the local treatment team;\n* Fit to undergo left-sided pancreatectomy according to the surgeon and anaesthesiologist;\n* Written informed consent\n\nExclusion Criteria:\n\n* Suspected pancreatic ductal adenocarcinoma;\n* Tumor or cyst larger than 8 cm;\n* Required resection or ablation of organs other than pancreas and spleen;\n* Tumor involvement or abutment of major vessels (celiac trunk, mesenteric artery or vena cava);\n* Pregnancy;\n* Body mass index \\>40 kg\u002Fm2;\n* Participation in another study with interference of study outcomes",{"count":291,"type":21},256,[24],"The DIPLOMA-3 trial is an international, multicenter, patient-blinded randomized controlled trial comparing laparoscopic and robot-assisted left-sided pancreatectomy. Patients with an indication for elective left-sided pancreatecomy for benign or premalignant lesions in the body or tail of the pancreas and considered eligible will be randomized between laparoscopic and robot-assisted resection.",[27,295,62,296,297,298,299,300,301,302],"Distal Pancreatectomy (DP)","Pancreatic Adenoma","Pancreatic Cyst","Pancreatic Cystadenoma","Surgery","Minimally Invasive Surgical Technique","Minimally Invasive Distal Pancreatectomy","Minimally Invasive Surgery",[304,305,269,306,307,268,308,309],"pancreas surgery","left-sided pancreatectomy","minimally invasive surgery","robot-assisted pancreatectomy","robotic pancreatectomy","laparoscopic pancreatectomy",{"date":311,"type":39},"2025-09-04",{"date":313,"type":39},"2025-06-01",{"date":315,"type":21},"2028-06-01",{"name":280,"class":46},{"id":318,"slug":319,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":323,"eligibilityCriteria":324,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":327,"conditions":328,"keywords":332,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":346},"100588683","a-new-clinical-pathway-for-personalized-management-of-borderline-resectable-and-locally-advanced-pancreatic-cancer-100588683","NCT06944587","A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer","A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer - Norwegian Pancreatic Cancer Trial-3 (NORPACT 3)","NORPACT-3","Inclusion Criteria:\n\n* Borderline resectable or locally advanced adenocarcinoma of the pancreas (NCCN, version 2, 2021) (Appendix 3)\n* Nx, M0 (UICC 8th version, 2016)\n* Cytological or histological confirmation of adenocarcinoma\n* Age \\>18 year\n* Considered able to receive primary chemotherapy and possible surgery\n* Written informed consent\n\nExclusion Criteria:\n\n* Co-morbidity or performance status precluding primary chemotherapy\n* Co-morbidity or performance status precluding pancreatectomy\n* Female patients in child-bearing age not using adequate contraception, pregnant or lactating women\n* Mental or physical disorders that could interfere with treatment of with the provision of informed consent\n* Any reason why, in the opinion of the investigator, the patient should not participate",{"count":326,"type":21},400,"NORPACT-3 is a nationwide, Norwegian single arm prospective study that evaluates the resectability rates and survival in patients with borderline resectable and locally advanced pancreatic cancer who received primary chemotherapy. Eligible patients are treated with primary chemotherapy possibly followed by surgical exploration and resection. All Norwegian centres performing pancreatic surgery have agreed to collaborate in this trial. The assignment of the medical intervention is not at the discretion of the investigator, but follow the national Norwegian guidelines regarding diagnostic work up, oncological and surgical treatment and follow up. The primary aim is a national resection rate of 50% in BRPC and 15% in LAPC in patients initiating primary chemotherapy, with adequate overall survival and morbidity\u002Fmortality (after resection median overall survival of 24 months, 1 year survival 80%, and 5 year survival \\>20% + 90 day postoperative mortality ≤5%, 90-day postoperative major morbidity (Clavien Dindo grade 3) ≤40%).",[329,330,27,331],"Locally Advanced Pancreatic Cancer","Borderline Resectable Pancreatic Cancer","Chemotherapy Effect",[333,334,330,329,27,331,335,336],"Primary chemotherapy","Resection rate","FDG PET-CT","ctDNA","2025-04-17",{"date":339,"type":39},"2025-04-25",{"date":341,"type":39},"2024-12-03",{"date":343,"type":21},"2028-12-31",{"name":345,"class":46},"Oslo University Hospital",5,{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":356,"conditions":357,"keywords":359,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":78},"100587981","effect-of-an-enhanced-recovery-after-surgery-program-on-outcomes-after-pancreatoduodenectomy-100587981","NCT06935448","Effect of an Enhanced Recovery After Surgery Program on Outcomes After Pancreatoduodenectomy","Effect of an Enhanced Recovery After Surgery Program on Outcomes After Pancreatoduodenectomy; Experience From Two Referral Centers in Central Greece.","Inclusion Criteria:\n\n* adult patients\n* diagnosis of pancreatic cancer\n* elective open pancreatic surgery\n\nExclusion Criteria:\n\n* age \\\u003C18 years\n* emergency pancreatic surgery\n* other surgical procedures\n* missing data\n* lost to follow-up",{"count":355,"type":21},170,"This study assesses whether patients with pancreatic cancer who undergo surgery experience improved outcomes following the implementation of a multidisciplinary care pathway, specifically an enhanced recovery after surgery (ERAS) program.\n\nThis pathway includes various interventions in the preoperative, intraoperative, and postoperative care of these patients, all aimed at enhancing their health status and postoperative results.",[27,358,264],"Enhanced Recovery After Surgery",[32,360,361,362],"enhanced recovery after surgery","pancreatic cancer resectable","outcomes research","2025-04-16",{"date":365,"type":39},"2025-04-20",{"date":367,"type":39},"2019-07-01",{"date":369,"type":21},"2025-05-30",{"name":371,"class":46},"University of Thessaly",{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":380,"enrollmentInfo":381,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":390,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":78},"100571004","phase-3-standard-or-prolonged-neoadjuvant-chemotherapy-before-surgery-for-brlapc-100571004","NCT06714604","Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR\u002FLAPC","Standard Versus Prolonged Neoadjuvant (Conversion) Chemotherapy to Prolong Survival of Patients With Borderline and Locally Advanced Pancreatic Cancer: a Phase III Randomized Controlled","ADVANTAGE","Inclusion Criteria:\n\n* Borderline or locally advanced pancreatic adenocarcinoma at diagnosis according to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, version 1.2022\n* Histo- or cytologically confirmed adenocarcinoma (preferably EUS-guided)\n* T1-4, Nx, M0 according to AJCC 8th edition\n* ECOG 0-1 and considered fit for the planned chemotherapy at the local hospital and surgery at the two national centers for BR\u002FLAPC\n* Written informed patient consent\n\nExclusion Criteria:\n\n* Co-morbidity precluding pancreatic surgery or chemotherapy\n* Contraindications to any of the drugs in the proposed treatment regimens\n* ECOG ≥2\n* Neuropathy ≥ grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE), version 6\n* Granulocyte count \\\u003C 1500 per cubic millimetre (\\\u003C 1,5 x 109\u002FL)\n* Platelet count \\\u003C 100 000 per cubic millimetre (\\\u003C 100 x 109\u002FL)\n* Serum creatinine \\> 1.5 UNL (upper limit normal range)\n* Albumin \\\u003C2,5 g\u002Fdl (\\\u003C25 g\u002FL)\n* Total bilirubin \\>3 x ULN\n* ASAT (SGOT) and ALAT (SGPT) \\>2.5 x institutional ULN\n* female patients in child-bearing age not using adequate contraception, pregnant or lactating women\n* mental or somatic disorders which could possibly interfere with informed consent, compliance or the planned treatments\n* previous oncologic treatment for PC within the past 5 years\n* participation in other clinical trial with an investigational product during the past 30 days\n* Any reason according to the investigator why the patient cannot comply with the protocol or is not suitable to participate","90 Years",{"count":382,"type":21},432,[185],"The goal of this multicenter randomized controlled phase III trial is to compare two durations of neoadjuvant chemotherapy (NAT) with mFOLFIRINOX or gemcitabine-nab-paclitaxel (GnP) before attempt for surgical resection in patients with borderline (BR) and locally advanced pancreatic cancer (LAPC). Patients with histologically confirmed non-metastatic BR\u002FLAPC evaluated to potentially tolerate any of the treatment regimens and pancreatic surgery will be randomized to receive either standard duration NAT with 6 cycles mFOLFIRINOX or 4 cycles GnP or prolonged duration NAT with either 12 cycles mFOLFIRINOX or 6 cycles GnP before attempt for surgical resection, provided there is no evidence of disease progression. The primary objective is to compare the overall survival at 24 months after randomization of all treated patients and among the resected patients with BR\u002FLAPC.",[386,387,388,389,299,27],"Locally Advanced Pancreatic Adenocarcinoma","Borderline Resectable Pancreatic Carcinoma","Pancreas Cancer","Neoadjuvant Chemotherapy",{"date":341,"type":39},{"date":392,"type":39},"2023-10-18",{"date":394,"type":21},"2033-12-31",{"name":396,"class":46},"Sahlgrenska University Hospital",{"id":398,"slug":399,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":17,"minAge":404,"maxAge":405,"enrollmentInfo":406,"targetDuration":407,"studyType":58,"phases":4,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":78},"100505064","management-of-traumatic-pancreas-transection-100505064","NCT05856474","Management of Traumatic Pancreas Transection","Surgical Management of Traumatic Pancreas Transection","Inclusion Criteria:\n\n* Diagnosed to have pancreas injury confirmed to pancreas injury by laparotomy.\n\nExclusion Criteria:\n\n* negative pancreas injury by laparotomy","1 Year","70 Years",{"count":158,"type":21},"2 Years","The goal of this observational study is to learn about the type of surgical effect on pancreas transection.\n\nThe main questions aims to answer are:\n\n* 1\\. does pancreas preserving able to decrease incidence of postoperative diabeters\n* 2\\. what is cause of major cause of postoperative morbidity and mortality in pancreas transection",[27],"2023-05-03",{"date":412,"type":39},"2023-05-12",{"date":414,"type":39},"2008-01-01",{"date":416,"type":21},"2030-01-01",{"name":418,"class":46},"National Cheng-Kung University Hospital"]